Jim Cramer was positive on Abbott Laboratories stock outlook back in 2024, advising to wait for a lower entry. The stock gained 28.54%, reflecting steady growth. ABT is rebounding with renewed investor interest in its healthcare products and diagnostics tools.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing